4//SEC Filing
Moran Sean F. 4
Accession 0001193125-25-251635
CIK 0001595097other
Filed
Oct 26, 8:00 PM ET
Accepted
Oct 27, 4:22 PM ET
Size
9.3 KB
Accession
0001193125-25-251635
Insider Transaction Report
Form 4
Moran Sean F.
Chief Financial Officer
Transactions
- Sale
Common Stock, par value $0.0001 per share
2025-10-24$17.02/sh−12,981$220,937→ 73,313 total - Exercise/Conversion
Common Stock, par value $0.0001 per share
2025-10-24$4.26/sh+12,981$55,299→ 86,294 total - Exercise/Conversion
Stock options (right to buy)
2025-10-24−12,981→ 10,386 totalExercise: $4.26From: 2024-02-13Exp: 2033-02-13→ Common Stock (12,981 underlying)
Footnotes (4)
- [F1]This amount includes 57,632 unvested RSUs subject to each grant's vesting schedule as previously reported.
- [F2]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025.
- [F3]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.79 to $17.38. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vested on February 13, 2024, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 13, 2024.
Documents
Issuer
Corbus Pharmaceuticals Holdings, Inc.
CIK 0001595097
Entity typeother
Related Parties
1- filerCIK 0001451495
Filing Metadata
- Form type
- 4
- Filed
- Oct 26, 8:00 PM ET
- Accepted
- Oct 27, 4:22 PM ET
- Size
- 9.3 KB